spacer
home > epc > autumn 2008 > home work
PUBLICATIONS
European Pharmaceutical Contractor

Home Work

In recent decades the types of therapy in research and the marketplace have undergone some radical transformations. Where most therapies were once squarely aimed at endemic diseases of the West, the recent biotechnology revolution has hugely increased the number of therapeutic targets, with more complex medicines – often parenteral – aimed at less common illnesses or at more specific sub groups of patients with more common conditions. For example, we are seeing oncology therapies targeting smaller sub groups of patients, the rise of therapies for orphan indications, the targeting of antibodies and proteins for specific complications of illness such as preventing SLE crisis and so on. The drive towards community medicine means an infrastructure has grown up to administer these medicines in the home and to run clinical trials in the same way.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Graham Wylie is CEO of the Medical Research Network Ltd, an affiliate company of Healthcare at Home. Graham, who trained as a physician, has 18 years of experience in clinical trials, starting with 10 years at Pfizer in clinical development and corporate HQ, with roles ranging from project management of trials to global implementation of standard trial processes and IT tools. He then joined Parexel International in 1999 as Medical Director for Northern Europe, progressing to Vice President of Account Management for Europe by 2003. In 2005 he joined Healthcare at Home to develop their clinical trials activities into a full business unit, known as ‘The Medical Research Network’, spinning the division off as a separate company in 2006.
spacer
Dr Graham Wylie
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Kallik’s Release 6 sets new benchmarks for speed, accuracy and efficiency

Tamworth, UK – 15 June 2019 – Global provider of labelling and artwork management solutions, Kallik, is launching an update to its AMS360 solution – its Release 6, transforming the experience of the business user, whilst defining new benchmarks for speed, accuracy, and efficiency of global labelling and artwork processes.
More info >>

White Papers

PROTEIN:PROTEIN INTERACTION ANALYSIS

IBA GmbH

Groth et al., 2007 and Jasencakova et al., 2010 Protein:protein-interactions (PPI) govern almost all important processes in living organisms. Thus, their rapid and accurate determination and investigation is a major challenge in life sciences. The extremely efficient and fast One-STrEP (Twin-Strep) system is suitable for the isolation of functional protein complexes and subsequent mass spectrometry analysis leads to the identification of protein complex components (Junttila et al., 2005) as it is shown in the following studies.
More info >>

 
Industry Events

Nordic Life Science Days 10/12 September 2019

10-12 September 2019, Malmo Sweden

Nordic Life Science Days is the largest Nordic partnering conference for the global Life Science industry. Bringing together the best talents in Life Science, offering amazing networking and partnering opportunities, providing inputs and content on the most recent trends. Nordic Life Science Days attracts leading decision makers from the Life Science sector, not only from biotech, pharma and medtech but also from finances, research, policy and regulatory authorities.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement